Nifty
Sensex
:
:
23250.10
76295.36
-82.25 (-0.35%)
-322.08 (-0.42%)

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 543245 | NSE: GLAND

1517.05
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1504.70
  •  1528.40
  •  1490.10
  •  1497.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  181133
  •  2745.52
  •  2220.95
  •  1411.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 25,734.95
  • 35.91
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 23,193.61
  • 1.28%
  • 2.81

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 4.71%
  • 3.30%
  • FII
  • DII
  • Others
  • 5.04%
  • 33.75%
  • 1.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.41
  • 16.56
  • 8.78

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.11
  • 6.89
  • -2.46

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.43
  • -0.01
  • -13.93

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 37.18

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 18.68

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
46.9
48.63
64.63
73.9
P/E Ratio
36.85
35.54
26.74
23.39
Revenue
5642
6120
6888
7614
EBITDA
1333
1363
1682
1996
Net Income
772
822
1108
1311
ROA
8
7.5
9.6
10.9
P/B Ratio
3.26
3.01
2.73
2.46
ROE
9.26
9.02
10.93
11.45
FCFF
718.31
346.53
469.38
844.67
FCFF Yield
2.64
1.27
1.73
3.1

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
1,384.05
1,545.15
-10.43%
1,405.83
1,373.42
2.36%
1,401.71
1,208.69
15.97%
1,537.45
785.01
95.85%
Expenses
1,024.10
1,188.76
-13.85%
1,108.78
1,049.35
5.66%
1,137.31
914.74
24.33%
1,178.80
616.59
91.18%
EBITDA
359.96
356.39
1.00%
297.06
324.08
-8.34%
264.40
293.95
-10.05%
358.65
168.42
112.95%
EBIDTM
26.01%
23.07%
21.13%
23.60%
18.86%
24.32%
23.33%
21.45%
Other Income
58.49
37.39
56.43%
59.66
53.15
12.25%
51.43
37.54
37.00%
42.15
38.94
8.24%
Interest
22.82
5.28
332.20%
6.11
6.05
0.99%
5.62
4.92
14.23%
9.96
2.20
352.73%
Depreciation
96.33
105.34
-8.55%
93.83
81.30
15.41%
91.96
65.31
40.81%
92.61
37.54
146.70%
PBT
299.30
283.16
5.70%
256.78
289.89
-11.42%
218.24
261.27
-16.47%
298.23
111.15
168.31%
Tax
94.61
91.30
3.63%
93.25
95.81
-2.67%
74.48
67.16
10.90%
105.81
32.47
225.87%
PAT
204.69
191.86
6.69%
163.53
194.08
-15.74%
143.76
194.10
-25.94%
192.42
78.68
144.56%
PATM
14.79%
12.42%
11.63%
14.13%
10.26%
16.06%
12.52%
10.02%
EPS
12.42
11.65
6.61%
9.93
11.78
-15.70%
8.73
11.79
-25.95%
11.68
4.78
144.35%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Net Sales
5,729.04
5,664.72
3,624.60
4,400.71
3,462.88
2,633.24
Net Sales Growth
16.63%
56.29%
-17.64%
27.08%
31.51%
 
Cost Of Goods Sold
2,201.81
2,173.09
1,685.42
2,109.11
1,219.00
836.07
Gross Profit
3,527.23
3,491.63
1,939.17
2,291.60
2,243.88
1,797.18
GP Margin
61.57%
61.64%
53.50%
52.07%
64.80%
68.25%
Total Expenditure
4,448.99
4,331.65
2,599.84
2,890.56
2,160.65
1,677.77
Power & Fuel Cost
-
229.99
124.84
95.05
74.58
78.50
% Of Sales
-
4.06%
3.44%
2.16%
2.15%
2.98%
Employee Cost
-
1,256.89
403.26
338.57
311.36
277.66
% Of Sales
-
22.19%
11.13%
7.69%
8.99%
10.54%
Manufacturing Exp.
-
327.19
194.23
179.85
436.84
391.88
% Of Sales
-
5.78%
5.36%
4.09%
12.61%
14.88%
General & Admin Exp.
-
217.36
120.53
94.28
58.66
57.77
% Of Sales
-
3.84%
3.33%
2.14%
1.69%
2.19%
Selling & Distn. Exp.
-
37.46
27.03
40.98
36.69
17.08
% Of Sales
-
0.66%
0.75%
0.93%
1.06%
0.65%
Miscellaneous Exp.
-
89.66
44.53
32.72
23.51
18.82
% Of Sales
-
1.58%
1.23%
0.74%
0.68%
0.71%
EBITDA
1,280.07
1,333.07
1,024.76
1,510.15
1,302.23
955.47
EBITDA Margin
22.34%
23.53%
28.27%
34.32%
37.61%
36.28%
Other Income
211.73
170.24
240.46
223.94
134.78
139.17
Interest
44.51
26.20
7.45
5.24
3.41
7.18
Depreciation
374.73
344.57
146.74
110.30
98.78
94.59
PBT
1,072.55
1,132.54
1,111.04
1,618.55
1,334.81
992.87
Tax
368.15
360.08
273.54
406.89
337.85
220.01
Tax Rate
34.32%
31.79%
25.94%
25.14%
25.31%
22.16%
PAT
704.40
772.46
781.04
1,211.66
996.96
772.86
PAT before Minority Interest
704.40
772.46
781.04
1,211.66
996.96
772.86
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.30%
13.64%
21.55%
27.53%
28.79%
29.35%
PAT Growth
6.93%
-1.10%
-35.54%
21.54%
29.00%
 
EPS
42.74
46.87
47.39
73.52
60.50
46.90

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Shareholder's Funds
8,723.84
7,958.72
7,157.62
5,903.24
3,646.24
Share Capital
16.47
16.47
16.43
16.36
15.49
Total Reserves
8,705.99
7,940.59
7,127.95
5,861.46
3,614.26
Non-Current Liabilities
488.60
89.68
93.97
80.31
80.78
Secured Loans
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
106.54
3.26
3.82
3.93
4.07
Long Term Provisions
137.21
0.00
0.00
0.00
0.00
Current Liabilities
1,398.36
729.13
582.02
512.53
359.02
Trade Payables
862.69
587.35
462.85
396.35
249.09
Other Current Liabilities
425.13
109.48
76.42
62.36
81.73
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
110.54
32.30
42.75
53.82
28.20
Total Liabilities
10,610.80
8,777.53
7,833.61
6,496.08
4,086.04
Net Block
3,946.75
1,570.55
1,502.19
954.23
968.10
Gross Block
5,011.68
2,294.95
2,081.32
1,430.70
1,347.81
Accumulated Depreciation
1,064.93
724.41
579.13
476.46
379.71
Non Current Assets
4,965.66
1,876.73
1,981.54
1,372.44
1,239.75
Capital Work in Progress
237.88
177.22
190.75
337.81
188.47
Non Current Investment
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
773.93
128.96
286.40
77.97
81.52
Other Non Current Assets
7.09
0.00
2.21
2.43
1.66
Current Assets
5,645.15
6,900.81
5,852.08
5,123.64
2,846.29
Current Investments
0.00
0.00
154.87
0.00
0.00
Inventories
1,655.24
1,945.30
1,185.67
1,275.17
756.28
Sundry Debtors
1,558.69
871.39
1,074.81
670.97
601.78
Cash & Bank
1,839.43
3,770.68
3,093.44
3,005.75
1,325.19
Other Current Assets
591.80
91.00
96.75
84.15
163.03
Short Term Loans & Adv.
489.19
222.44
246.55
87.60
91.80
Net Current Assets
4,246.79
6,171.68
5,270.05
4,611.11
2,487.27
Total Assets
10,610.81
8,777.54
7,833.62
6,496.08
4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Cash From Operating Activity
996.80
363.97
790.77
604.93
700.93
PBT
1,132.54
1,054.58
1,618.55
1,334.81
992.87
Adjustment
223.60
38.19
-28.27
17.30
32.15
Changes in Working Capital
-53.20
-417.94
-393.01
-435.76
-79.94
Cash after chg. in Working capital
1,302.95
674.83
1,197.28
916.35
945.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-306.15
-310.87
-406.51
-311.43
-244.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,756.91
1,208.19
-1,002.62
-1,524.00
-766.08
Net Fixed Assets
-227.74
-200.10
-503.56
-232.23
Net Investments
-2,377.58
154.87
-162.48
-0.55
Others
848.41
1,253.42
-336.58
-1,291.22
Cash from Financing Activity
-799.42
14.92
34.90
1,238.46
-6.87
Net Cash Inflow / Outflow
-1,559.53
1,587.08
-176.95
319.39
-72.01
Opening Cash & Equivalents
1,908.89
318.82
492.46
169.50
236.40
Closing Cash & Equivalent
357.09
1,908.89
318.82
492.46
169.50

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Book Value (Rs.)
529.56
483.12
434.84
359.30
234.25
ROA
7.97%
9.40%
16.91%
18.84%
18.91%
ROE
9.26%
10.34%
18.61%
20.97%
21.29%
ROCE
13.63%
14.04%
24.85%
28.00%
27.39%
Fixed Asset Turnover
1.55
1.66
2.51
2.49
1.95
Receivable days
78.29
97.99
72.40
67.08
83.41
Inventory Days
116.00
157.65
102.05
107.06
104.83
Payable days
121.78
113.72
74.35
96.63
52.71
Cash Conversion Cycle
72.51
141.92
100.10
77.51
135.53
Total Debt/Equity
0.04
0.00
0.00
0.00
0.00
Interest Cover
44.23
142.61
309.77
392.33
139.24

News Update:


  • Gland Pharma receives USFDA’s approval for Acetaminophen Injection
    3rd Apr 2025, 12:27 PM

    This product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older

    Read More
  • USFDA concludes pre-approval inspection at Visakhapatnam facility of Gland Pharma
    25th Feb 2025, 16:27 PM

    The said inspection was concluded with three form 483 observations

    Read More
  • Gland Pharma reports 7% rise in Q3 consolidated net profit
    3rd Feb 2025, 18:12 PM

    Total consolidated income of the company decreased by 8.85% at Rs 1442.55 crore for Q3FY25

    Read More
  • Gland Pharma - Quarterly Results
    3rd Feb 2025, 17:22 PM

    Read More
  • Gland Pharma gets EIR from USFDA for Pashamylaram facility
    18th Jan 2025, 15:01 PM

    USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024

    Read More
  • Gland Pharma gets EIR from USFDA for Hyderabad facility
    16th Jan 2025, 14:28 PM

    USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 22, 2024 and July 25, 2024

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.